
|Videos|December 8, 2017
Dr. Graff Discusses Sipuleucel-T in Patients With mCRPC
Author(s)Julie Graff, MD
Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer.
Advertisement
Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Sipuleucel-T is well tolerated in this population, says Graff. Some patients have some itching or a slight fever, but both are both easily managed.
Although it has shown benefit, one of the challenges with sipuleucel-T is that it does not shrink tumors, Graff adds.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
5



































